Reltecimod - Atox Bio

Drug Profile

Reltecimod - Atox Bio

Alternative Names: AB-103; p 2 TA

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Atox Bio
  • Class Antibacterials; Peptides
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Skin and soft tissue infections
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Skin and soft tissue infections
  • No development reported Sepsis

Most Recent Events

  • 04 Dec 2017 Atox Bio plans a phase II trial for Acute kidney injury in 2018
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Sepsis(In volunteers) in USA (IV, Infusion)
  • 25 Sep 2017 Atox Bio receives the third tranche of a grant from the Biomedical Advanced Research and Development Authority for the development of reltecimod for Skin and soft tissue infections (Necrotising soft tissue infections)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top